mometasone, intranasal (Rx)

Brand and Other Names:Nasonex
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

nasal spray suspension

  • 50mcg/spray
more...

Allergic Rhinitis

Nasal symptoms of allergic rhinitis

2 sprays (100 mcg) in each nostril qDay

Seasonal Allergic Rhinitis

Nasal congestion associated with seasonal allergic rhinitis; also indicated for prophylaxis of seasonal allergic rhinitis

Treatment: 2 sprays (100 mcg) in each nostril qDay

Prophylaxis: 2 sprays (100 mcg) in each nostril qDay; initiate 2-4 weeks prior to pollen season

Nasal Polyps

2 sprays (100 mcg) in each nostril q12hr; qDay dosing may be effective in some patients

Dosage Forms & Strengths

nasal spray suspension

  • 50mcg/spray
more...

Allergic Rhinitis

Nasal symptoms of allergic rhinitis

<2 years: Safety and efficacy not established

2-12 years: 1 spray (50 mcg) in each nostril qDay

≥12 years: 2 sprays (100 mcg) in each nostril qDay

Seasonal Allergic Rhinitis

Nasal congestion associated with seasonal allergic rhinitis; also indicated for prophylaxis of seasonal allergic rhinitis

Treatment

  • <2 years: Safety and efficacy not established
  • 2-12 years: 1 spray (50 mcg) in each nostril qDay
  • >12 years: 2 sprays (100 mcg) in each nostril qDay

Prophylaxis

  • <12 years: Safety and efficacy not established
  • >12 years: 2 sprays (100 mcg) in each nostril qDay; initiate 2-4 weeks prior to allergy season

Nasal Polyps

Safety and efficacy not established

Next:

Adverse Effects

>10%

Headache

Pharyngitis

Cough

Viral infection

Epistaxis

1-10%

Diarrhea

Dyspnea

Vomiting

Dysmenorrhea

Musculoskeletal pain

Myalgia

Conjunctivitis

Otitis media

Flu-like syndrome

<1%

Anaphylaxis

Angioedema

Growth suppression

Nasal candidiasis

Taste disturbance

Nasal septal perforation

Nasal burning and irritation

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Recent nasal surgery, nasal trauma, nasal septum ulcers (until healing has occurred)

Cautions

Monitor for vision change or, with history of increased IOP, glaucoma, or for cataracts

Respiratory tract fungal or bacterial infections, viral/parasitic infections, or ocular herpes simplex may occur

Potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex

More serious or fatal course of chickenpox or measles in susceptible patients

Risk for hypercorticism and adrenal suppression with higher-than-normal doses

Potential reduction of growth velocity in children

Previous
Next:

Pregnancy & Lactation

Pregnancy category: C

Lactation: Unknown whether distributed in breast milk

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Corticosteroid with potent anti-inflammatory properties; elicits effects on various cells, including mast cells and eosinophils; also elicits effects on inflammatory mediators (eg, histamine, eicosanoids, leukotrienes, cytokines)

Absorption

Bioavailability: <1%

Minimal systemic absorption occurs, mostly by small amount swallowed during nasal administration

Distribution

Protein bound: 98-99%

Metabolism

Metabolism: CYP3A4

Elimination

Half-life: 5.8 hr

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous